JPWO2023097259A5 - - Google Patents

Info

Publication number
JPWO2023097259A5
JPWO2023097259A5 JP2024530570A JP2024530570A JPWO2023097259A5 JP WO2023097259 A5 JPWO2023097259 A5 JP WO2023097259A5 JP 2024530570 A JP2024530570 A JP 2024530570A JP 2024530570 A JP2024530570 A JP 2024530570A JP WO2023097259 A5 JPWO2023097259 A5 JP WO2023097259A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
selective agonist
alkyl
rarγ selective
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024530570A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541472A5 (https=
JP2024541472A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080408 external-priority patent/WO2023097259A1/en
Publication of JP2024541472A publication Critical patent/JP2024541472A/ja
Publication of JP2024541472A5 publication Critical patent/JP2024541472A5/ja
Publication of JPWO2023097259A5 publication Critical patent/JPWO2023097259A5/ja
Pending legal-status Critical Current

Links

JP2024530570A 2021-11-23 2022-11-23 がん治療のためにＲＡＲγアゴニストを使用する方法 Pending JP2024541472A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163282547P 2021-11-23 2021-11-23
US63/282,547 2021-11-23
PCT/US2022/080408 WO2023097259A1 (en) 2021-11-23 2022-11-23 METHODS OF USING RARγ AGONISTS FOR CANCER TREATMENT

Publications (3)

Publication Number Publication Date
JP2024541472A JP2024541472A (ja) 2024-11-08
JP2024541472A5 JP2024541472A5 (https=) 2025-12-08
JPWO2023097259A5 true JPWO2023097259A5 (https=) 2025-12-08

Family

ID=85706524

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024530570A Pending JP2024541472A (ja) 2021-11-23 2022-11-23 がん治療のためにＲＡＲγアゴニストを使用する方法

Country Status (11)

Country Link
US (3) US11793835B2 (https=)
EP (1) EP4436574A4 (https=)
JP (1) JP2024541472A (https=)
KR (1) KR20240111779A (https=)
CN (1) CN118574611A (https=)
AU (1) AU2022398628A1 (https=)
CA (1) CA3239689A1 (https=)
CL (1) CL2024001542A1 (https=)
IL (1) IL313052A (https=)
MX (1) MX2024006212A (https=)
WO (1) WO2023097259A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11976021B2 (en) 2022-06-27 2024-05-07 Io Therapeutics, Inc. Synthesis of tetrahydronaphthalenols and uses thereof
WO2025240479A1 (en) * 2024-05-14 2025-11-20 Children's National Medical Center Trained tumor specific t-cell for immunotherapy and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
DE60136477D1 (de) * 2000-10-02 2008-12-18 Hoffmann La Roche Retinoide zur behandlung von emphysem
WO2005046726A2 (en) * 2003-11-12 2005-05-26 Allergan, Inc. Combinations for inhibiting cell growth which contains an inhibitor of human ck1 alpha activity and a rxr agonist
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
BRPI0616454A2 (pt) 2005-09-30 2011-06-21 Vitae Pharmaceuticals, Inc. métodos de tratamento de cáncer
US20070185055A1 (en) 2006-02-06 2007-08-09 Guang Liang Jiang Method for treating cachexia with retinoid ligands
SG11201810951RA (en) * 2016-06-10 2019-01-30 Io Therapeutics Inc Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
KR20200029544A (ko) * 2017-07-13 2020-03-18 아이오 테라퓨틱스, 인크. 암 면역요법을 위해 면역 조절제와 조합된 면역조절 레티노이드 및 렉시노이드 화합물
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers

Similar Documents

Publication Publication Date Title
RU2708374C2 (ru) Комбинированная терапия для лечения рака
DK2269603T3 (en) TREATMENT OF BREAST TUMORS WITH A RAPAMYCIN DERIVATIVE IN COMBINATION WITH EXEMESTAN
Torres et al. New therapeutic avenues in ulcerative colitis: thinking out of the box
US10471030B2 (en) Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
JP2020531429A (ja) Ｈｉｖカプシド阻害剤のコリン塩形態
JP2020515581A (ja) Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法
CN108938642A (zh) 免疫相关和炎性疾病的治疗
US12295962B2 (en) Polymorphic compounds and uses thereof
JP7246309B2 (ja) 免疫応答を調節するためのオキサビシクロヘプタン
Curigliano et al. Alpelisib in combination with everolimus±exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study
TWI858843B (zh) 哌類化合物和ｐｄ－１抑制劑或ｐｄ－ｌ１抑制劑的組合物以及其在製備抗腫瘤藥物中的用途
KR20190018486A (ko) 암의 예방 및/또는 치료를 위한 화합물, 조성물 및 방법
Fitzpatrick et al. VPR-254: an inhibitor of ROR-gamma T with potential utility for the treatment of inflammatory bowel disease
CN119454695A (zh) Csf1r激酶抑制剂及其用途
TW202114647A (zh) 用於治療具有高間質壓力的腫瘤受試者的癌症的小分子抑制劑
US20210353648A1 (en) Grapiprant unit dosage forms
US20220226281A1 (en) Compounds for use in anti-cancer immunotherapy
CN116490177B (zh) 通路调节剂、含其的药物组合物、其用途和采用其的治疗方法
JP2024541472A (ja) がん治療のためにＲＡＲγアゴニストを使用する方法
JPWO2023097259A5 (https=)
BR112020021739A2 (pt) tratamento de doenças ou distúrbios de pele pela liberação do anticorpo anti-osmrbeta
Li et al. Curcumin improves experimentally induced colitis in mice by regulating follicular helper T cells and follicular regulatory T cells by inhibiting interleukin-21.
WO2021143928A1 (zh) 用于治疗类风湿性关节炎的喹啉衍生物
JP2020535140A5 (https=)
San Miguel et al. Idecabtagene vicleucel (IDE-CEL; BB2121), a BCMA-targeted CAR T cell therapy in patients with relapsed and refractory multiple myeloma: initial KARMMA results